Evidence map›Paper›PMID 40375661›Full record

ArticleThe journal of physical chemistry. A2025

TrIP2: Expanding the Transformer Interatomic Potential Demonstrates Architectural Scalability for Organic Compounds.

Joshua Ebbert, Bryce Hedelius, Jyothish Joy, Daniel H Ess, Dennis Della Corte

Abstract read
In one paragraph

Article in The journal of physical chemistry. A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joshua EbbertDepartment of Physics and Astronomy, Brigham Young University, Provo, Utah 84604, United States.
Bryce HedeliusDepartment of Physics and Astronomy, Brigham Young University, Provo, Utah 84604, United States.
Jyothish JoyDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84604, United States.ORCID 0000-0002-2260-4329
Daniel H EssDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah 84604, United States.
Dennis Della CorteDepartment of Physics and Astronomy, Brigham Young University, Provo, Utah 84604, United States.ORCID 0000-0002-8884-9724

Funding

Engineering Enzymes for Improved Stability and Retained Function via Rapid Design-Build-Test-Learn Cycles integrating AI/Physics based predictions with Cell-free Protein Synthesis Experimental TestingR15GM155803 · NIGMS · BRIGHAM YOUNG UNIVERSITY · PI DELLA CORTE, DENNIS · 2024 to 2024
$449k
NIGMS NIH HHS R15 GM155803
6 · The paper itself

Abstract

TrIP2 is an advanced version of the transformer interatomic potential (TrIP) trained on the expanded ANI-2x data set, including more diverse molecular configurations with sulfur, fluorine, and chlorine. It leverages the equivariant SE(3)-transformer architecture, incorporating physical biases and continuous atomic representations. TrIP was introduced as a highly promising transferable interatomic potential, which we show here to generalize to new atom types with no alterations to the underlying model design. Benchmarking on COMP6 energy and force calculations, structure minimization tasks, torsion drives, and applications to molecules with unexpected conformational energy minima demonstrates TrIP2's high accuracy and transferability. Direct architectural comparisons demonstrate superior performance against ANI-2x, while holistic model evaluations─including training data and level-of-theory considerations─show comparative performance with state-of-the-art models like AIMNet2 and MACE-OFF23. Notably, TrIP2 achieves state-of-the-art force prediction performance on the COMP6 benchmarks and closely approaches DFT-optimized structures in torsion drives and geometry optimization tasks. Without requiring any architectural modifications, TrIP2 successfully capitalizes on additional training data to deliver enhanced generalizability and precision, establishing itself as a robust and scalable framework capable of accommodating future expansions or applications to new domains with minimal reengineering.

Identifiers

PMID40375661
PMCPMC12401561

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.